Induction toripalimab plus chemotherapy sequential concurrent chemoradiotherapy with nimotuzumab followed by toripalimab maintenance in stage IVB hypopharyngeal squamous cell carcinoma: a single-arm phase 2 study
Journal for ImmunoTherapy of Cancer · 2026-07 · 14 (7) · e015325
DOI: 10.1136/jitc-2026-015325 ↗Kurz gefasst
Klinische Studie (Phase II) in der Zeitschrift Journal for ImmunoTherapy of Cancer, online erschienen am 24.07.2026. Verfasst von Zeyang Geng und 14 weiteren Autor:innen. Beteiligte Einrichtung: Senior Department of Otolaryngology Head and Neck Surgery, The 6th Medical Center of Chinese PLA General Hospital, Chinese PLA Medical School, Beijin…. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Chemoradiotherapy, Hypopharyngeal Neoplasms, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: National Clinical Research Center for Otolaryngologic Diseases.
Themen: Onkologische Pflege
Abstract (Originalsprache)
Background
Optimal induction chemoimmunotherapy sequential concurrent chemoradiotherapy (cCRT) in locally advanced hypopharyngeal squamous cell carcinoma (HSCC) remains undefined. This study aimed to evaluate toripalimab plus chemotherapy sequential cCRT with nimotuzumab, followed by toripalimab maintenance in unresectable stage IVB HSCC.
Methods
In this single-arm, open-label, phase 2 study, untreated patients received two 21-day cycles of induction toripalimab 240 mg (d1) plus nab -paclitaxel 230 mg/m 2 (d1) and cisplatin/nedaplatin 40 mg/m 2 (d1-2) sequential cCRT (helical tomotherapy; nab -paclitaxel 230 mg/m 2 (d1, 22, 43)) with nimotuzumab 200 mg weekly for 7 weeks. Subsequently, toripalimab maintenance was administered for eight cycles. Primary endpoint was progression-free survival (PFS).
Results
From March 16, 2022 to April 24, 2024, 31 patients completed induction chemoimmunotherapy. With a median follow-up of 31 months, median PFS and overall survival (OS) were not reached; 2-year PFS and OS rates were 67.7% and 86.4%. The 2-year larynx preservation rate was 93.3%. 30 (96.8%) patients achieved the best objective response, with 28 (90.3%) complete responses and 2 (6.5%) partial responses. The most common grade 3–4 treatment-related adverse events (TRAEs) were radiation-induced oropharyngeal mucositis and decreased appetite (each 46.9%). No grade 5 and fatal TRAEs occurred. No difficulties in speech and swallowing functions were reported in 96.8% of patients. There was no significant association between PFS and PD-L1 combined positive score, epidermal growth factor receptor expression, tumor-infiltrating T-lymphocytes, tumor mutational burden, or genetic alterations. High baseline peripheral CD3 + and CD8 + CD28 + T-cell levels were associated with favorable PFS. Exploratory biomarker analyses identified that patients without disease progression after maintenance exhibited significantly higher levels of CD8 + CD28⁻ T cells with a memory phenotype and lower B-cell levels.
Conclusions
This exploratory study demonstrated preliminary efficacy and larynx preservation with manageable toxicity, possibly supporting further evaluation of induction toripalimab plus chemotherapy sequential cCRT with nimotuzumab, followed by toripalimab maintenance in stage IVB HSCC. Peripheral lymphocytes may warrant further investigation as candidate biomarkers in locally advanced disease. Trial registration number NCT05860335 ; ChiCTR2300074672.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Senior Department of Otolaryngology Head and Neck Surgery, The 6th Medical Center of Chinese PLA General Hospital, Chinese PLA Medical School, Beijing, China.
- National Clinical Research Center for Otolaryngologic Diseases, Beijing, China.
- State Key Laboratory of Hearing and Balance Science, Beijing, China.
- Key Laboratory of Hearing Science, Ministry of Education, Beijing, China.
- Beijing Key Laboratory of Hearing Impairment Prevention and Treatment, Beijing, China.
- Department of Pathology, The First Medical Center of Chinese PLA General Hospital, Beijing, China.
Förderung
- National Clinical Research Center for Otolaryngologic Diseases
Zitieren
APA
Geng, Z., Chen, N., Wei, J., Liu, K., Gu, X., Gou, X., Liang, R., Wu, L., Sui, J., Liu, L., Meng, L., Ma, L., Liu, T., Yang, S., & Zhang, X. (2026). Induction toripalimab plus chemotherapy sequential concurrent chemoradiotherapy with nimotuzumab followed by toripalimab maintenance in stage IVB hypopharyngeal squamous cell carcinoma: a single-arm phase 2 study. Journal for ImmunoTherapy of Cancer, 14(7), e015325. https://doi.org/10.1136/jitc-2026-015325
Vancouver
Geng Z, Chen N, Wei J, Liu K, Gu X, Gou X, et al. Induction toripalimab plus chemotherapy sequential concurrent chemoradiotherapy with nimotuzumab followed by toripalimab maintenance in stage IVB hypopharyngeal squamous cell carcinoma: a single-arm phase 2 study. Journal for ImmunoTherapy of Cancer. 2026;14(7):e015325. doi:10.1136/jitc-2026-015325
BibTeX
@article{Geng2026,
author = {Geng, Zeyang and Chen, Nanxiang and Wei, Jian and Liu, Kun and Gu, Xiang and Gou, Xiangnan and Liang, Robert and Wu, Liangliang and Sui, Jinshu and Liu, Luotong and Meng, Lingling and Ma, Lin and Liu, Tianyi and Yang, Shiming and Zhang, Xinxin},
title = {Induction toripalimab plus chemotherapy sequential concurrent chemoradiotherapy with nimotuzumab followed by toripalimab maintenance in stage IVB hypopharyngeal squamous cell carcinoma: a single-arm phase 2 study},
journal = {Journal for ImmunoTherapy of Cancer},
year = {2026},
volume = {14},
number = {7},
pages = {e015325},
doi = {10.1136/jitc-2026-015325}
}
EUVIMED